Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 11 for:    MDMA | First posted from 07/30/2018 to 03/21/2020

MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD (VALLMDMA_001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04264026
Recruitment Status : Not yet recruiting
First Posted : February 11, 2020
Last Update Posted : February 12, 2020
Sponsor:
Collaborator:
Multidisciplinary Association for Psychedelic Studies
Information provided by (Responsible Party):
Shannon Remick, VA Loma Linda Health Care System

Brief Summary:

This will be a single-site, open-label phase 2 study designed to test the feasibility of administering MDMA in conjunction with psychotherapy for combat-related treatment-resistant PTSD in US military veterans currently enrolled in VA. MDMA will be given in conjunction with structured psychotherapy in three single-dose psychotherapy sessions in a hospital setting over the course of 12 weeks, along with preparatory and integration psychotherapy sessions in-between each active-dose session. The overall objective of this study is to evaluate the risks, benefits, and feasibility of MDMA used in conjunction with manualized psychotherapy, on reduction of symptoms, or remission of PTSD, as evaluated by standard clinical measures, in a VA Healthcare System.

The primary outcome measure for the study is the Clinician-Administered PTSD Scale (CAPS-5), a semi-structured interview used in the majority of clinical trials for PTSD, which will be assessed at baseline, primary endpoint, and at the long-term 12-month follow-up visit. Secondary safety and efficacy measures will also be collected.

The planned duration of this study is 1-3 years, with each active treatment period lasting approximately 12 weeks, along with a long-term follow-up 12 months after the last active-drug session.


Condition or disease Intervention/treatment Phase
Post Traumatic Stress Disorder Combat Stress Disorders Drug: 3,4-methylenedioxymethamphetamine Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Single-site, open-label study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label Phase 2 Study of MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD
Estimated Study Start Date : March 2020
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023

Arm Intervention/treatment
Experimental: Open Label
Participants will receive an initial dose of 80 mg of 3,4-methylenedioxymethamphetamine (MDMA) and an optional supplemental dose of 40 mg MDMA during the first Experimental Session. In the second and third Experimental Sessions, the participant will receive an initial dose of 120 mg MDMA and an optional supplemental dose of 60 mg MDMA.
Drug: 3,4-methylenedioxymethamphetamine
Bottles are labeled with a unique container number, protocol number, IMP name, lot number, sponsor name and a statement that the IMP is restricted to clinical trial use only.
Other Name: MDMA




Primary Outcome Measures :
  1. Change in total score of CAPS-5 [ Time Frame: baseline, 2 months, 12-months follow-up ]
    CAPS-5 is the gold standard measurement tool for evaluating PTSD in current FDA-approved medication trials for PTSD. The CAPS-5 is a standardized method to evaluate the frequency and intensity dimensions of each PTSD symptom, impact on functioning, overall severity of the symptom complex, and a dichotomous outcome based on DSM-5 criteria on whether the participant meets diagnostic criteria for PTSD. CAPS-5 scores will be measured at baseline, 2 months after the last drug session, and at the long-term 12-month follow-up.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants must be eligible for VA healthcare
  2. Participants must meet DSM 5 criteria for combat-related PTSD (within the past 6 months). PTSD must be defined as treatment-resistant.
  3. Participants must have been exposed to combat in the current-era war.
  4. Participants must be 18-55 years old.
  5. Participants must be generally healthy overall without any significant medical comorbidities (see exclusion criteria).
  6. Participants must be willing to refrain from taking any psychiatric medications during the study period, including gabapentin or any other anticonvulsants. If they are being treated with psychoactive medications during recruitment, participants must be willing and determined safe (by study physician(s)) to undergo medically-supervised withdrawal from these medications. The medications will be withdrawn in an appropriate fashion to minimize any withdrawal effects. The participants must be able to refrain from starting any new medications during the study period. The only exception to this will be in the case of rescue medications that may be administered in the event of a crisis during the experimental study sessions.
  7. Agree that, for one week preceding an MDMA session will refrain from:

    1. Taking any herbal supplement (except with prior approval of the research team);
    2. Taking any nonprescription medications (with the exception of non-steroidal anti-inflammatory drugs or acetaminophen unless with prior approval of the research team);
    3. Taking any prescription medications, with the exception of birth control pills, thyroid hormones or other medications approved by the research team.
  8. Are proficient in speaking and reading English.
  9. Must meet capacity and consent for treatment.
  10. Participants who are engaged in non-PTSD psychotherapy at the time of study screening, may continue to see their therapist during the course of the study. If seeing a non-VA therapist, participants must sign a release for the investigators to communicate directly with their therapist. Subjects may not change therapists, increase the frequency of therapy or commence any new type of therapy until after the evaluation session 2 months after the final experimental session.
  11. Participants of childbearing potential and age must have a negative pregnancy test and must agree to use an effective form of birth control during the study period.
  12. Participants must be willing to stay overnight at the hospital after each experimental session.
  13. Agree to have transportation other than driving themselves home on the day after an MDMA session.
  14. Are willing to follow restrictions and guidelines concerning medications, consumption of food, beverages, alcohol, nicotine, or illicit substances.
  15. Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal.
  16. Must agree to inform the investigators within 48 hours of any medical conditions and procedures.
  17. Agree to not participate in any other interventional clinical trials during the duration of this study.
  18. Must be able to swallow pills.

Exclusion Criteria:

  1. Individuals with only non-combat related PTSD. Note: participants will not be excluded for having multiple traumas so long as one of those is combat-related.
  2. Participants currently engaged in PTSD psychotherapy.
  3. Lack a stable living situation or supportive system.
  4. Any person unable to give adequate informed consent.
  5. Participants of childbearing potential who are pregnant, nursing, or of childbearing age unwilling/unable to practice an effective means of birth control.
  6. People with a history of, or a current psychotic disorder, bipolar affective disorder or personality disorders.
  7. Have a current eating disorder.
  8. Have current major depressive disorder with psychotic features.
  9. Would present a serious risk to others as established through clinical interview and contact with treating psychiatrist.
  10. People with evidence or history of significant hematological, cardiovascular, cerebrovascular, coronary, pulmonary, endocrine, renal, gastrointestinal, hepatic, immunocompromising, neurological disease (including seizure disorder or cognitive impairment). Patients with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded.
  11. Have uncontrolled hypertension using the standard criteria of the American Heart Association (values of 140/90 milligrams of Mercury [mmHg] or higher assessed on three separate occasions).
  12. Have a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds [ms] for men or >470 ms for women corrected by Bazett's formula).
  13. Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
  14. Require use of concomitant medications that prolong the QT/QTc interval during Experimental Sessions.
  15. Have history of hyponatremia or hyperthermia.
  16. People weighing less than 50 kg.
  17. People with a serious suicide risk or who are likely to require hospitalization within the course of the study.
  18. Individuals who require ongoing treatment with psychoactive medications.
  19. Individuals meeting DSM-5 criteria for active substance use disorder for any substance other than caffeine or nicotine assessed.
  20. Have received Electroconvulsive Therapy (ECT) within 12 weeks of enrollment.
  21. Currently engaged in compensation litigation whereby financial gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders.
  22. Unable to ensure reliable transportation to and from study visits or have unstable housing.
  23. Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to questionnaires, and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion. Any participant who is likely to require hospitalization related to suicidal ideation and behavior will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04264026


Contacts
Layout table for location contacts
Contact: Angela J Hawley, MA 909-825-7084 ext 2411 angela.hawley@va.gov
Contact: Allie Kaigle, PharmD, BCPP 909-787-4814 allie.kaigle2@va.gov

Locations
Layout table for location information
United States, California
VA Loma Linda Health Care System
Loma Linda, California, United States, 92357
Contact: Angela J Hawley, MA    909-825-7084 ext 2411    angela.hawley@va.gov   
Contact: Maria I Rodriguez    909-825-7084 ext 6159    maria.rodriguez9@va.gov   
Principal Investigator: Shannon Remick, MD         
Sub-Investigator: Allie Kaigle, PharmD, BCPP         
Sponsors and Collaborators
VA Loma Linda Health Care System
Multidisciplinary Association for Psychedelic Studies
Investigators
Layout table for investigator information
Principal Investigator: Shannon Remick, MD Staff Psychiatrist

Layout table for additonal information
Responsible Party: Shannon Remick, Principal Investigator, VA Loma Linda Health Care System
ClinicalTrials.gov Identifier: NCT04264026    
Other Study ID Numbers: 1311
First Posted: February 11, 2020    Key Record Dates
Last Update Posted: February 12, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No sharing planned

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Shannon Remick, VA Loma Linda Health Care System:
Veterans
Refractory PTSD
PTSD
MDMA
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Combat Disorders
Pathologic Processes
Trauma and Stressor Related Disorders
Mental Disorders
N-Methyl-3,4-methylenedioxyamphetamine
Hallucinogens
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Adrenergic Agents